Health
FDA Grants Accelerated Approval to Rybrevant Faspro for Head and Neck Cancer After Platinum and Immunotherapy
A subcutaneous antibody from Johnson & Johnson becomes the first new option in a decade for people whose recurrent head and neck tumours outlasted standard treatment, with a confirmatory study still owed.
Nov 6, 2026
